› Forums › General Melanoma Community › Relapse of melanoma after successful adoptive T-cell therapy
- This topic has 3 replies, 1 voice, and was last updated 10 years, 8 months ago by benp.
- Post
-
- August 8, 2013 at 1:10 pm
http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12038/full
http://onlinelibrary.wiley.com/doi/10.1111/pcmr.12038/full
The results of Landsberg et al. have important clinical implications if the phenotypic plasticity of melanoma cells in an inflammatory microenvironment is validated in a larger cohort of patients with melanoma after ACT. Down-modulation of gp100 expression and concurrent up-regulation of NGFR expression of melanoma cells in an inflammatory environment raises the possibility of using ACT with a cocktail of CAR-engineered T cells with dual or multiple specificities to target more than one melanoma antigen to ensure complete regression of tumor lesions. For this, a personalized approach of analyzing melanoma antigen expression on tumor cells before and after ACT therapy will be essential for the selection of CAR-engineered T cells with defined tumor antigen specificity. The proposed approach may enhance the long term disease-free survival of patients with metastatic melanoma.
************************************************************************************************
INTERESTING. My question, "would aspirin improve the ACT/TIL success"?
- Replies
- You must be logged in to reply to this topic.